Symbiotec Pharmalab Reports Q1 FY27 Earnings

Consolidated revenue stood at INR 218 crore, with a net profit of INR 14 crore for the quarter.

Reader Takeaway: Stable API cash flows support heavy capital expenditure in fermentation and injectables, though initial startup costs weigh on current margins.

What just happened

Symbiotec Pharmalab delivered Q1 FY27 earnings showing a 7% year-on-year revenue increase to INR 218 crore. The company’s core API business generated INR 215 crore with steady 6% growth. Net profitability was tempered by INR 34 crore in operational and depreciation costs associated with scaling new Biotech CDMO and complex injectable divisions.

Why this matters

The company is pivoting from a pure-play API manufacturer to a multi-vertical biotech provider. Management confirmed they have secured major long-term take-or-pay contracts, including deals for insulin and alternative proteins, which are expected to generate milestone revenues starting in H2 FY27.

Business Performance

The API segment remains the primary driver, operating at 70%-80% capacity with gross margins exceeding 60%. Simultaneously, the firm is building out a 600 kL Phase 1 fermentation facility and has filed its first molecule ANDA in the complex injectables space.

Management Outlook

Management has provided guidance for 20% revenue growth and 25% EBITDA growth for FY27. They plan to sustain an annual capital expenditure of INR 200 to 250 crore over the next three years to meet contractual demands.

Risks to watch

Execution risk remains the primary concern. Timely commercialization of the fermentation expansion and successful regulatory approval for pending injectable filings are critical. Short-term margin volatility is expected due to depreciation from under-utilized assets.